DE60203461D1 - Makrolidcitrat-haltige Formulierungen mit kontrollierter Freisetzung - Google Patents

Makrolidcitrat-haltige Formulierungen mit kontrollierter Freisetzung

Info

Publication number
DE60203461D1
DE60203461D1 DE60203461T DE60203461T DE60203461D1 DE 60203461 D1 DE60203461 D1 DE 60203461D1 DE 60203461 T DE60203461 T DE 60203461T DE 60203461 T DE60203461 T DE 60203461T DE 60203461 D1 DE60203461 D1 DE 60203461D1
Authority
DE
Germany
Prior art keywords
macrolide
controlled release
citrate
release formulations
containing controlled
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60203461T
Other languages
English (en)
Other versions
DE60203461T2 (de
Inventor
Hardeep Wadhwa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ind-Swift Ltd
Original Assignee
Ind-Swift Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ind-Swift Ltd filed Critical Ind-Swift Ltd
Publication of DE60203461D1 publication Critical patent/DE60203461D1/de
Application granted granted Critical
Publication of DE60203461T2 publication Critical patent/DE60203461T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
DE60203461T 2001-10-01 2002-10-01 Makrolidcitrat-haltige Formulierungen mit kontrollierter Freisetzung Expired - Lifetime DE60203461T2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
INDE20011018 2001-10-01
INDE20011019 2001-10-01
IN1018DE2001 2001-10-01
IN1019DE2001 2001-10-01

Publications (2)

Publication Number Publication Date
DE60203461D1 true DE60203461D1 (de) 2005-05-04
DE60203461T2 DE60203461T2 (de) 2006-02-09

Family

ID=26324885

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60203461T Expired - Lifetime DE60203461T2 (de) 2001-10-01 2002-10-01 Makrolidcitrat-haltige Formulierungen mit kontrollierter Freisetzung

Country Status (9)

Country Link
US (1) US6642276B2 (de)
EP (1) EP1302205B1 (de)
JP (1) JP2003212757A (de)
AT (1) ATE291922T1 (de)
BR (1) BR0208526A (de)
CA (1) CA2405918A1 (de)
DE (1) DE60203461T2 (de)
DK (1) DK1302205T3 (de)
PT (1) PT1302205E (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US20050249786A1 (en) * 2001-09-28 2005-11-10 Solubest Ltd. Hydrophilic dispersions of nanoparticles of inclusion complexes of amorphous compounds
US20040185097A1 (en) * 2003-01-31 2004-09-23 Glenmark Pharmaceuticals Ltd. Controlled release modifying complex and pharmaceutical compositions thereof
WO2004100880A2 (en) * 2003-05-06 2004-11-25 Nirmal Mulye Controlled release formulation of erythromycin derivatives
EP2529730A1 (de) * 2003-06-16 2012-12-05 ANDRX Pharmaceuticals LLC. Orale Zusammensetzung mit verlängerter Freisetzung
WO2005004919A2 (en) * 2003-07-02 2005-01-20 Eurand, Inc. Extended release systems for macrolide antibiotics
WO2005009364A2 (en) 2003-07-21 2005-02-03 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
CA2533292C (en) 2003-07-21 2013-12-31 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
CA2533178C (en) 2003-07-21 2014-03-11 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
US20050049209A1 (en) * 2003-08-06 2005-03-03 Chen Andrew Xian Pharmaceutical compositions for delivering macrolides
WO2005016311A1 (en) 2003-08-11 2005-02-24 Advancis Pharmaceutical Corporation Robust pellet
AU2004264356B2 (en) 2003-08-12 2011-01-27 Shionogi, Inc. Antibiotic product, use and formulation thereof
JP5686494B2 (ja) 2003-08-29 2015-03-18 シオノギ インコーポレイテッド 抗生物質製剤、その使用法及び作成方法
EP1663169A4 (de) 2003-09-15 2010-11-24 Middlebrook Pharmaceuticals In Antibiotisches produkt, seine verwendung und formulierung
US8168228B2 (en) * 2003-10-17 2012-05-01 Sandoz Ag Antibiotic clarithromycin micropellet compositions
US20050084540A1 (en) * 2003-10-17 2005-04-21 Indranil Nandi Taste masking antibiotic composition
US20050101547A1 (en) * 2003-11-06 2005-05-12 Sadatrezaei Mohsen Stabilized azithromycin composition
AU2005235237A1 (en) * 2004-03-24 2005-11-03 Lupin Limited Clarithromycin extended release formulation
US8188067B2 (en) 2004-04-01 2012-05-29 Teva Pharmaceutical Industries Ltd. Formulations of 6-mercaptopurine
WO2005099665A2 (en) * 2004-04-01 2005-10-27 Teva Pharmaceutical Industries Ltd. Imroved formulations of 6-mercaptopurine
JP2008505124A (ja) 2004-07-02 2008-02-21 アドバンシス ファーマスーティカル コーポレイション パルス送達用錠剤
JP5004236B2 (ja) * 2005-02-09 2012-08-22 キッセイ薬品工業株式会社 口腔内崩壊錠
US20070087056A1 (en) * 2005-08-09 2007-04-19 Claudia Guthmann Pharmaceutical form with sustained pH-independent active ingredient release for active ingredients having strong pH-dependent solubility
US20070087055A1 (en) * 2005-10-14 2007-04-19 David Jan Directly compressible extended release alprazolam formulation
US8778924B2 (en) 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US20070202164A1 (en) * 2006-02-28 2007-08-30 Hutchison Medipharma Enterprises Limited Andrographis Extract Formulations
WO2007126039A1 (ja) * 2006-04-28 2007-11-08 Shionogi & Co., Ltd. マクロライド系抗生物質の被覆製剤
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
EP2030613A1 (de) * 2007-08-17 2009-03-04 Abbott GmbH & Co. KG Herstellung von Zusammensetzungen mit hauptsächlich nichtkristallinen eingebetteten Makrolid-Antibiotika
CA2721728A1 (en) * 2008-04-18 2009-10-22 Teva Pharmaceutical Industries Ltd. Treatment of inflammatory bowel disease with 6-mercaptopurine
CN101624412B (zh) * 2008-07-10 2012-07-04 刘力 大环内酯类衍生物及其制备和用途
EP2283824B1 (de) 2009-07-30 2017-04-19 Special Products Line S.p.A. Zusammensetzungen und Formulierungen, die auf quellbaren Matrizen basieren, zur verzögerten Freisetzung von schlecht löslichen Arzneimitteln, wie zum Beispiel Clarithromycin
JP2013180961A (ja) * 2012-02-29 2013-09-12 Astellas Pharma Inc Ｗｓ７２７７１３含有固形製剤
EP2671571A1 (de) 2012-06-05 2013-12-11 Sanovel Ilac Sanayi ve Ticaret A.S. Formulierungen von Clarithromycin mit gesteuerter Freisetzung
CN103776945A (zh) * 2014-01-16 2014-05-07 扬子江药业集团南京海陵药业有限公司 罗红霉素胶囊的质量控制方法
US20170105996A1 (en) 2015-10-16 2017-04-20 Teva Pharmaceutical Industries, Ltd. Treatment of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis with delayed-release 6-mercaptopurine
CN105997929A (zh) * 2016-06-23 2016-10-12 南京华宽信息咨询中心 一种罗红霉素胶囊及其制备方法
CN106580903B (zh) * 2016-11-17 2019-12-13 江苏豪森药业集团有限公司 罗红霉素缓释药物组合物
CN109248155B (zh) * 2018-09-27 2020-08-11 北京鑫开元医药科技有限公司 一种罗红霉素胶囊及其制备工艺

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0188040B1 (de) * 1985-01-11 1991-08-14 Abbott Laboratories Limited Feste Zubereitung mit langsamer Freisetzung
US5457111A (en) * 1991-09-05 1995-10-10 Abbott Laboratories Macrocyclic immunomodulators
US5705190A (en) * 1995-12-19 1998-01-06 Abbott Laboratories Controlled release formulation for poorly soluble basic drugs
US5750510A (en) * 1997-04-04 1998-05-12 Abbott Laboratories 3-descladinose-2,3-anhydroerythromycin derivatives
US6551616B1 (en) * 1997-04-11 2003-04-22 Abbott Laboratories Extended release formulations of erythromycin derivatives
JPH10335732A (ja) * 1997-06-02 1998-12-18 Toshiba Microelectron Corp レーザ用制御回路および制御方法
US6239112B1 (en) * 1998-07-09 2001-05-29 Merial, Inc. Water miscible macrolide solutions
IT1303671B1 (it) * 1998-07-28 2001-02-23 Nicox Sa Sali dell'acido nitrico con farmaci attivi nel trattamento dipatologie del sistema respiratorio
SI20150A (sl) * 1999-02-19 2000-08-31 Lek, Tovarna Farmacevtskih In Direktno stisljivi matriks za nadzorovano sproščanje celodnevne doze klaritromicina
TR200000054A2 (tr) * 2000-01-05 2001-08-21 Sanovel İlaç San. Ve Ti̇c. Anoni̇m Şi̇rketi̇ Klaritromisin içeren sürekli salım sağlayan tablet formülasyonları.

Also Published As

Publication number Publication date
EP1302205B1 (de) 2005-03-30
US20030077325A1 (en) 2003-04-24
ATE291922T1 (de) 2005-04-15
CA2405918A1 (en) 2003-04-01
EP1302205A1 (de) 2003-04-16
BR0208526A (pt) 2004-08-10
US6642276B2 (en) 2003-11-04
JP2003212757A (ja) 2003-07-30
DK1302205T3 (da) 2005-08-08
DE60203461T2 (de) 2006-02-09
PT1302205E (pt) 2005-06-30

Similar Documents

Publication Publication Date Title
DE60203461D1 (de) Makrolidcitrat-haltige Formulierungen mit kontrollierter Freisetzung
HUP0101237A1 (hu) Elnyújtott kioldódású gyógyszerkészítmények
AU2002357012A1 (en) Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof
NO20043998L (no) Oral administreringsform for tungtloselige basiske aktive virkestoffer
DE69936002D1 (de) Angepasster löffel zur oralen medikamenten-verabreichung
WO2003002136A3 (en) Stable formulation of modified glp-1
AU2002239282A1 (en) Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
MXPA03003895A (es) Formulaciones de hidrocodona de liberacion controlada.
DE60100186D1 (de) Orale pharmazeutische formulierungen von benzimidazolderivaten und verfahren zu ihrer herstellung
HUP0201877A2 (hu) Hal zselatint tartalmazó, gyorsan diszpergálódó dózis formák
NO20042565L (no) Orale farmasoytiske produkter inneholdende 17 beta-ostradiol-3-lavere alkanoat, fremgangsmater for administrering av disse og fremgangsmater for fremstilling derav
HUP0302319A3 (en) Pharmaceutical composition for oral administration of active ingredient
WO2001022791A8 (en) Controlled release compositions comprising nimesulide
HUP0203312A3 (en) Pharmaceutically active sulfonamide derivatives, process for their preparation, and pharmaceutical compositions and their use
NO20040268L (no) Nye 2H-pyridazin-3-derivater, farmasoytiske preparater inneholdende slike og fremgangsmate for fremstilling av den aktive ingrediensen
IL159217A0 (en) An oral pharmaceutical formulation comprising a basic pharmaceutically active ingredient having ph-dependent solubility, a process for the manufacture thereof and use thereof in medicine
DE60131760D1 (de) Vorrichtung zur verabreichung von physiologisch aktiven wirkstoffen in pulverform
CY1107819T1 (el) Φαρμακευτικη διαμορφωση της ολανζαπινης
ATA59499A (de) Pharmazeutische, tolperison enthaltende zubereitung zur oralen verabreichung
AU2001287977A1 (en) Controlled release formulations for oral administration
AU2001272314A1 (en) Oral formulations for localized colonic release and the method of preparation thereof
ATE409474T1 (de) Tryptamin-derivative und analoge verbindungen, und pharmazeutische formulationen daraus
SE0001916D0 (sv) Novel formulation
FR2793685B1 (fr) Compositions pharmaceutiques, destinees a l'administration par voie orale de phloroglucinol et leur preparation
WO1999047172A3 (en) Oral pharmaceutical compositions to be taken without liquids, which contain inclusion complexes

Legal Events

Date Code Title Description
8364 No opposition during term of opposition